|
EP3580219A1
|
|
Process for the preparation of remimazolam and solid state forms of remimazolam salts
|
|
WO2018129227A1
|
|
Novel crystalline forms of selinexor and process for their preparation
|
|
EP3555061A1
|
|
Solid state forms of apalutamide
|
|
US2016068299A1
|
|
Frangible shipping carton and associated methods
|
|
WO2013025203A1
|
|
Resolution of tetrahydrofolic acid derivatives
|
|
WO2012134445A1
|
|
An improved process for the preparation of paliperidone
|
|
WO2012121701A1
|
|
Process for the resolution of racemic (±)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide
|
|
WO2012078147A1
|
|
A process for the preparation of intermediates useful in the production of aliskiren
|
|
BRPI0915256A2
|
|
stable chewing gum composition
|
|
EP2331519A1
|
|
Improved synthesis of hexahydrodibenzopyranones
|
|
US2009139894A1
|
|
Medicament dispenser and method
|
|
WO2008076229A1
|
|
Atomoxetine formulations and associated methods
|
|
US2009101536A1
|
|
Systems for increasing compliance with a medicament treatment regime
|
|
BRPI0714304A2
|
|
Controlled release formulations and associated methods
|
|
US7985419B1
|
|
Divisible tablet and associated methods
|
|
US7921999B1
|
|
Peelable pouch for transdermal patch and method for packaging
|
|
EP1928378A2
|
|
Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
|
|
US2008031932A1
|
|
Transdermal atomoxetine formulations and associated methods
|
|
CN101277686A
|
|
Formulations and methods for enhancing the transdermal penetration of a drug
|
|
US2007065494A1
|
|
Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
|
